July 24, 2024
Make sure what and which your portfolio is holding and where it is going to be worth; as well as any share pricing costs you will have to make along the way
Pre-open Indications: 4 Negative and 2 Sell into Strength
News: Sangamo Therapeutics (SGMO +$0.01) positive topline results from the P3 AFFINE trial (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy that SGMO and Pfizer (PFE) is co-developing with and licensing to Pfizer for the treatment of adults with moderately severe to severe hemophilia A.
A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations
Never leave an investor uninformed
July 15, 2024
Stock purchase agreement with Ridgeback Capital Investments L.P.
LENZ intends to use the net proceeds from the PIPE financing, with its existing cash, cash equivalents, and marketable securities, to support the regulatory, pre-commercial and potential commercial launch activities for LNZ100 as well as for working capital and general corporate purposes.
July 23, 2024
Share pricing continues its incline, who’s buying – electronic trading while I believe investors are hesitant about this market’s moves and sector travels as earnings season looms
News: Mesoblast Ltd (MESO +$0.72) the FDA has accepted its Biologics License Application (BLA) resubmission for Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). FDA anticipates a decision on or before the FDA’s Prescription Drug User Fee Act (PDUFA) goal date of 1/7/25.
I say today what others won't, so you can do what others can't by sticking to the FACTS!
Never leave an investor uninformed!
July 15, 2024
Stock purchase agreement with Ridgeback Capital Investments L.P. LENZ intends to use the net proceeds from the PIPE financing, with its existing cash, cash equivalents, and marketable securities, to support the regulatory, pre-commercial and potential commercial launch activities for LNZ100 as well as for working capital and general corporate purposes.
June 27, 2024
BCLI is trading at $0.34 or -$0.0451 or -$11.56% Maxim Group LLC is acting as the sole placement agent for the offering. … Walk away …
June 14, 2024
RARE closed down -$1.52 at $43.12 with a -$1.94 or -4.50% to $41.18 The offering is expected to close on or about 6/17/24, subject to satisfaction of customary closing conditions. J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering.
July 24, 2024
RegMed Investors’ (RMi) pre-open: Is the juice worth the squeeze
July 24, 2024
RegMed Investors’ (RMi) pre-open: Is the juice worth the squeeze
July 23, 2024
RegMed Investors (RMi) Closing Bell: in the bag for today
July 23, 2024
RegMed Investors (RMi) Closing Bell: in the bag for today
July 23, 2024
RegMed Investors’ (RMi) pre-open: a trend or a bend?
July 22, 2024
RegMed Investors (RMi) Closing Bell: rebound as algos and electronic trading buy in
July 22, 2024
RegMed Investors (RMi) Closing Bell: rebound as algos and electronic trading buy in
July 22, 2024
RegMed Investors’ (RMi) pre-open: sector struggles as earnings set a frown
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
